

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis

Alberto Ferrari,¹ Alessandra Carobbio,¹ Arianna Masciulli,¹ Arianna Ghirardi,¹ Guido Finazzi,² Valerio De Stefano,³ Alessandro Maria Vannucchi⁴ and Tiziano Barbui¹

¹FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo; ²Hematology Division, Papa Giovanni XXIII Hospital, Bergamo; ³Institute of Hematology, Catholic University, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome and ⁴CRIMM-Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.221234

Received: March 7, 2019.

Accepted: May 20, 2019.

Pre-published: May 23, 2019.

Correspondence: *TIZIANO BARBUI* - tbarbui@asst-pg23.it

Supplementary tables and figures


Supplementary Table 1: Logistic models – fixed effects estimates

	OR	P-value	95% CI
Mortality			
Follow-up duration	1.55	0.007**	1.12,2.13
Age	1.21	0.000***	1.09,1.33
Antiplatelet	3.93	0.547	0.05,338.10
Anticoagulant	1.16	0.861	0.22,6.02
CV risk	0.00	0.192	0.00,20.48
Previous thrombosis	1.04	0.968	0.15,7.12
MF			
Follow-up duration	1.55	0.000***	1.31,1.83
Age	1.06	0.021*	1.01,1.11
AML			
Follow-up duration	1.21	0.001***	1.08,1.36
Age	1.02	0.336	0.98,1.07
Thrombosis			
Follow-up duration	1.20	0.016*	1.03,1.39
Age	1.13	0.000***	1.08,1.19
Antiplatelet	5.30	0.156	0.53,53.06
Anticoagulant	1.51	0.323	0.67,3.42
CV risk	0.00	0.001***	0.00,0.04
Previous thrombosis	2.08	0.174	0.72,5.99

Exponentiated coefficients

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Observed vs fitted



Supplementary Figure 1: observed vs fitted plots of logistic GLMM for each outcome. Circle sizes are weighted by study dimension. Predicted values are in good agreement with observed events.